EncepHeal Therapeutics Receives $300,000 SBIR grant

EncepHeal Therapeutics has been awarded a Phase I SBIR grant worth $304,217 from the National Institute on Drug Abuse (NIDA) to begin research on its licensed modafinil analogues as potential pharmacotherapies. The money from this grant is budgeted to be used to conduct a variety of screening assays centered around tests to prove i) efficacy, and ii) show little to no abuse liability. The goal is to determine a lead compound to move forward through IND and into clinical trials. This award is a major stepping stone for bridging the drug development gap for our ultimate vision of breaking the cycle of addiction with next-generation neurotherapeutics.  Pending a good Phase I outcome EncepHeal will look toward additional support through a Phase II grant.